Global Autoimmune Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Autoimmune Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies

Global Autoimmune Partnering 2010 to 2017 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Autoimmune partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Autoimmune partnering agreement structure

Autoimmune partnering contract documents

Top Autoimmune deals by value

Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Autoimmune deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Autoimmune deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2010. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Global Autoimmune Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Autoimmune deal trends since 2010

Access Autoimmune deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Autoimmune partner companies

Comprehensive access to over 500 links to actual Autoimmune deals entered into by the world's biopharma companies

Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Autoimmune opportunities

Uncover companies actively partnering Autoimmune opportunities

Global Autoimmune Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune partnering over the years
2.3. Autoimmune partnering by deal type
2.4. Autoimmune partnering by industry sector
2.5. Autoimmune partnering by stage of development
2.6. Autoimmune partnering by technology type
2.7. Autoimmune partnering by therapeutic indication

Chapter 3 -Financial deal terms for Autoimmune partnering
3.1. Introduction
3.2. Disclosed financials terms for Autoimmune partnering
3.3. Autoimmune partnering headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune royalty rates

Chapter 4 - Leading Autoimmune deals and dealmakers
4.1. Introduction
4.2. Most active in Autoimmune partnering
4.3. List of most active dealmakers in Autoimmune
4.4. Top Autoimmune deals by value

Chapter 5 - Autoimmune contract document directory
5.1. Introduction
5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Autoimmune therapeutic target

Appendices

Appendix 1 - Directory of Autoimmune deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Autoimmune deals by deal type 2010 to 2017
Appendix 3 - Directory of Autoimmune deals by stage of development 2010 to 2017
Appendix 4 - Directory of Autoimmune deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Autoimmune partnering since 2010
Figure 2: Autoimmune partnering by deal type since 2010
Figure 3: Autoimmune partnering by industry sector since 2010
Figure 4: Autoimmune partnering by stage of development since 2010
Figure 5: Autoimmune partnering by technology type since 2010
Figure 6: Autoimmune partnering by indication since 2010
Figure 7: Autoimmune deals with a headline value
Figure 8: Autoimmune deals with upfront payment values
Figure 9: Autoimmune deals with milestone payment
Figure 10: Autoimmune deals with royalty rates
Figure 11: Active Autoimmune dealmaking activity- 2010 to 2017
Figure 12: Top Autoimmune deals by value since 2010
  • Celiac Disease - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Celiac Disease - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Celiac Disease in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Celiac Disease prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Celiac......
  • Celiac Disease - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Celiac Disease - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Celiac Disease for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Celiac Disease forecasted market share for ten years to 2025 segmented by seven major markets. In addition, the report includes the historical and forecas......
  • Celiac Disease - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, " Celiac Disease -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Celiac Disease. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Celiac Disease. This report provides information on the therapeutic development for Celiac Disease, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well ......
  • Autoimmune Drugs Industry Forecasts - China Focus
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 78
    This study focuses on China's Autoimmune Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. Th......
  • Autoimmune Drugs Companies in China
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 71
    This study focuses on China's Autoimmune Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of......
  • Autoimmune Drugs Markets in China
    Published: 15-May-2017        Price: US 4000 Onwards        Pages: 201
    China's demand for Autoimmune Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indu......
  • Celiac Disease - Epidemiology Insights to 2023
    Published: 31-Jan-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight's "Celiac Disease (CD) - Epidemiology Insights-2023" report provides an overview of the Celiac Disease and current scenario of the disease in the 7MM, i.e., United States and EU5 countries (France, Germany, Italy, Spain and UK) and Japan. It also includes the global historical and forecasted epidemiological data for the total prevalent cases and diagnosed prevalent cases of Celiac Disease from 2013-2023. Celiac disease is a genetic autoimmune disease where the indiges......
  • Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016
    Published: 21-Dec-2016        Price: US 2000 Onwards        Pages: 97
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H2 2016, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predispo......
  • Systemic Lupus Erythematosus - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 419
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2016, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs